ZD1839 (Gefitinib, 'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma. (Q40397259)
Jump to navigation
Jump to search
scientific article published on August 2005
Language | Label | Description | Also known as |
---|---|---|---|
English | ZD1839 (Gefitinib, 'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma. |
scientific article published on August 2005 |
Statements
ZD1839 (Gefitinib, 'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma (English)
Fuminori Teraishi
Takanori Watanabe
Yasuhisa Tango
Takeshi Kawashima
Tatsuo Umeoka
Masahiko Nisizaki
Noriaki Tanaka
Toshiyoshi Fujiwara
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference